Farah Champsi, Director at Kite Pharma, Inc. (KITE), sold 38,336 shares at $82.59 ($3.2M) on 2017-04-28, disclosed to the SEC on 2017-05-01.
Open-market sale of $3.2M KITE by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $82.77 | 16,551 | $1.4M | 43.2% |
| 2 | $82.77 | 16,551 | $1.4M | 43.2% |
| 3 | $82.59 | 2,617 | $216K | 6.8% |
| 4 | $82.59 | 2,617 | $216K | 6.8% |
| Total | $82.75 avg | 38,336 | $3.2M | 100% |
| Filing → |
| KITE | SELL | 2017-04-17 | $19.0M | — | Filing → |
| KITE | SELL | 2015-07-02 | $41.4M | — | Filing → |
| CMRX | SELL | 2013-10-23 | $6.9M | — | Filing → |